EyePoint vs RenovoRx
EYPT and RNXT side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EYPT and RNXT compare
RenovoRx is the larger company, worth 1.8 times as much as EyePoint ($46.9M against $26.4M).
RenovoRx keeps more of each dollar of sales as profit, with a net margin of −469% compared with −13281% at EyePoint.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EYPT | RNXT |
|---|---|---|
| Size and price | ||
| Market cap | $26.4M | $46.9M |
| Share price | $0.306 | $1.04 |
| Change, 1 year | −97.4% | 4.0% |
| Change, 5 years | −98.2% | −84.2% |
| Beta (5Y) | 1.71 | 1.30 |
| Employees | 214 | 17 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.2× (better) | 16.9× |
| P/B | 0.2× (better) | 5.1× |
| FCF yield | −1134% | −26.0% (better) |
| Fair value | – | $0.465 |
| Margin of safety | – | −124% |
| Growth | ||
| Revenue growth (TTM) | −93.9% | – |
| Revenue growth, 5Y average | −1.8% | – |
| Profitability | ||
| Gross margin | – | 84.0% |
| Operating margin | −13642% | −489% (better) |
| Net margin | −13281% | −469% (better) |
| FCF margin | −11599% | −440% (better) |
| Return on equity | −222% | −150% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.30 | 5.65 (better) |
| Altman Z-score | −17.69 | −1.55 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −21.3% |
| Shareholder yield | 0.00% (better) | −21.3% |
| Ownership | ||
| Held by institutions | 108% | 20.4% |
| Held by insiders | 0.96% | 6.0% |
| Insider net buying, 12 months | −$1.9M | $66.9K (better) |
| Short interest, % of float | 12.9% | 2.4% |
Go deeper
- EYPT stock overview
- EYPT income statement
- EYPT valuation and score
- RNXT stock overview
- RNXT income statement
- RNXT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.